Home / Business and Economy / India's ₹25K Cr Drug Procurement Undergoing Major Overhaul
India's ₹25K Cr Drug Procurement Undergoing Major Overhaul
20 Feb
Summary
- Government procures ₹20,000-25,000 crore worth of medicines annually.
- New norms aim to reduce costs by favoring bulk purchases.
- Policy change seeks to replace expensive local chemist indents.
India's government is implementing a major overhaul of its drug testing and sampling procedures, a move that significantly impacts its annual medicine procurement valued at ₹20,000-25,000 crore. This initiative is crucial for enhancing transparency and efficiency within the Central Government Health Scheme (CGHS).
The revised policy is expected to optimize expenditure by prioritizing bulk procurements over costly individual chemist indents. While initial buffer stock purchases may require upfront investment, the long-term objective is to achieve cost savings and improve the overall value for money.
These changes are designed to ensure better quality control and reduce opportunities for corruption. The government anticipates that the new norms will lead to more efficient distribution and availability of essential medicines across the country.
